<DOC>
	<DOCNO>NCT00002004</DOCNO>
	<brief_summary>To determine safety profile maximum tolerate dose ( MTD ) recombinant soluble human CD4 ( rCD4 ) therapy patient AIDS AIDS relate complex ( ARC ) . To assess pharmacokinetic property rCD4 human . To obtain preliminary indication antiviral effect rCD4 patient AIDS AIDS relate complex ( ARC ) .</brief_summary>
	<brief_title>A Phase I Study Safety Pharmacokinetics Recombinant CD4 ( rCD4 ) Patients With AIDS AIDS-Related Complex</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>AIDS-Related Complex</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV1 seropositivity . Diagnosis AIDS AIDS relate complex ( ARC ) . Failure tolerate respond zidovudine ( AZT ) decide decline AZT therapy . The ability sign write informed consent form prior treatment . A willingness abstain experimental therapy HIV infection entire study period . A life expectancy least 3 month . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Serious active opportunistic infection . Malignancies Kaposi 's sarcoma . Concurrent Medication : Excluded : Zidovudine ( AZT ) . Corticosteroids . Nonsteroidal antiinflammatory agent ( NSAI ) . Other experimental therapy . Patients follow exclude : Serious active opportunistic infection . Malignancies Kaposi 's sarcoma . Prior Medication : Excluded within 3 week study entry : Zidovudine ( AZT ) . Chemotherapy . Immunomodulators . Other experimental therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 1990</verification_date>
	<keyword>Recombinant Proteins</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antigens , CD4</keyword>
	<keyword>AIDS-Related Complex</keyword>
</DOC>